Tokyo, Japan, February 6, 2017 --- Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced today that Teijin’s board of directors has elected Akihisa Nabeshima, currently corporate officer of the Teijin Group and senior executive director of Teijin Pharma, as its next president. Nabeshima will assume his new role on April 1.
Hiroshi Uno, the current president of the company, will assume the post of responsible for healthcare business of the Teijin Limited, on the same day.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 150 companies and around 16,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY790.7 billion (USD 7.4 billion) and total assets of JPY 823.4 billion (USD 7.7 billion) in the fiscal year ending March 31, 2016. Please visit www.teijin.com.
